Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
A phase 3 trial of Technetium-99m tilmanocept in Head and neck squamous cell carcinoma, run by Navidea Biopharmaceuticals, recorded as terminated on the registry.
Overview
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT00911326 by Navidea Biopharmaceuticals, with 101 participants recorded, started 2009-05 and due to reach its primary completion in 2013-08. Interventions recorded: Lymphoseek. Conditions recorded: Head and Neck Squamous Cell Carcinoma (HNSCC).
Linked to the drug Technetium-99m tilmanocept because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTrial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Shares Navidea Biopharmaceuticals, Technetium-99m tilmanocept and the tag pipeline.
- TrialBreast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Shares Navidea Biopharmaceuticals, Technetium-99m tilmanocept and the tag pipeline.
- TrialPersonalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Shares Technetium-99m tilmanocept and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialResponse Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
Shares Head and neck squamous cell carcinoma and the tag pipeline.